Abstract

The role of maintenance therapy after first-line platinum and pemetrexed for malignant pleural mesothelioma is unknown. We performed the first-to-date randomized trial to determine if continuation of pemetrexed would improve progression-free survival over that of observation and found that primary endpoint was not different between study arms. Therefore, we cannot recommend pemetrexed continuation maintenance for treatment of malignant pleural mesothelioma.

Original languageEnglish
Pages (from-to)553-561.e1
JournalClinical Lung Cancer
Volume21
Issue number6
DOIs
StatePublished - Nov 2020

Keywords

  • Continuation pemetrexed
  • Phase II study
  • Progression-free survival
  • Unresectable mesothelioma

Fingerprint

Dive into the research topics of 'Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901'. Together they form a unique fingerprint.

Cite this